PSCA: prostate stem cell antigen and uses thereof
AssigneeThe Regents of the University of California
InventorsRobert E. Reiter, Owen N. Witte, Douglas C. Saffran, Aya Jakobovits
Life of this patent
Estimating the term…
Abstract
The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.
Claims52
An antibody which specifically binds to PSCA on the surface of carcinoma cells, and is internalized within the carcinoma cells to which it binds.
An antibody which specifically binds to PSCA on the surface of carcinoma cells, and is cytotoxic to the carcinoma cells to which it binds.
An antibody which specifically binds to PSCA on the surface of carcinoma cells, and is cytostatic to the carcinoma cells to which it binds.
An antibody which specifically binds PSCA on the cell surface of carcinoma cells, and is internalized and kills the carcinoma cells to which it reacts.
An antibody which specifically binds to PSCA on the surface of carcinoma cells, and is internalized and is cytostatic to the carcinoma cells to which it binds.
An antibody, comprising an antigen binding site, wherein the antigen binding site recognizes and binds the N terminal region of PSCA.
An antibody, comprising an antigen binding site, wherein the antigen binding site recognizes and binds the C terminal region of PSCA.
An antibody, comprising an antigen binding site, wherein the antigen binding site recognizes and binds the middle region of PSCA.
A method for prolonging the life of a subject with a cancer associated with PSCA, comprising administering to the subject a monoclonal antibody which binds to PSCA in an amount effective so as to inhibit the cancer, thereby prolonging the life of the subject.
A method of inhibiting the growth of cancer cells expressing PSCA, comprising administering to a patient a combination of monoclonal antibodies which bind to PSCA in an amount effective so as to inhibit growth of the cancer cells.
Dependencies are inferred from the claim text.